STOCK TITAN

Spectral AI Inc - MDAIW STOCK NEWS

Welcome to our dedicated page for Spectral AI news (Ticker: MDAIW), a resource for investors and traders seeking the latest updates and insights on Spectral AI stock.

Spectral AI Inc (MDAIW) pioneers AI-driven medical diagnostics through its DeepView System, transforming wound care assessments with real-time imaging technology. This dedicated news hub provides investors and medical professionals with essential updates on the company's advancements in predictive healthcare solutions.

Access authoritative information on regulatory milestones, product developments, and strategic partnerships that shape Spectral AI's position in medical technology. Our curated collection includes press releases about FDA clearances, clinical trial results, and innovations in emergency care diagnostics.

Key updates cover Spectral AI's work with military medical units, enhancements to its proprietary algorithms, and expansions into new healthcare markets. The platform serves as your primary source for understanding how MDAIW's technology improves decision-making in critical care environments.

Bookmark this page for structured access to verified company announcements. Check regularly to stay informed about Spectral AI's contributions to AI-powered diagnostics and their impact on patient outcomes across care settings.

Rhea-AI Summary
Spectral AI, Inc. (MDAI) announces the enrollment of the first patient in the pivotal study to validate DeepView AI® for burn size and healing assessment. The study is expected to be the final clinical trial before seeking FDA marketing authorization in 2025. The company continues to utilize $251 million of non-dilutive government funding since 2019 to validate DeepView for burn indication and other clinical indications like diabetic foot ulcers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) has announced the hiring of Peter M. Carlson as Chief Financial Officer. Carlson brings a strong track record in senior financial executive roles at public companies, including healthcare entities, and will play a crucial role in navigating the financial landscape and strategic opportunities for Spectral AI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) is an AI company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care. The company announced its participation in the Benchmark 12th Annual Discovery One-on-One Conference in New York City. Spectral AI's DeepView® System has received a significant contract from the U.S. Government and has been validated through multiple clinical studies for assessing burn wounds and diabetic foot ulcers. The company expects to submit applications for FDA, UKCA, and CE mark approval for its DeepView® System in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences AI
Rhea-AI Summary
Spectral AI, Inc. (MDAI) appoints Erich Spangenberg as Chairman of the Executive Committee and Nominating and Corporate Governance Committee. Erich, the Company's largest shareholder, brings 40 years of experience in IP-related financings and is recognized as a top 50 IP strategist. Spectral AI received $251 million in non-dilutive funding from the US Government, and Erich aims to maximize shareholder value and reflect the intrinsic value of MDAI stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management AI
-
Rhea-AI Summary
Spectral AI, Inc. (Nasdaq: MDAI) announced Q3 2023 financial results, affirming full-year revenue guidance for 2023 and 2024. The company highlighted progress in developing and commercializing its AI-Driven DeepView® System wound healing assessment technology. The system provides immediate wound healing potential assessment, with high accuracy for burn and diabetic foot ulcers. The company is preparing for the commercial launch of the DeepView® System as early as 2024, following regulatory approvals. Q3 2023 financial results overview showed a decline in R&D revenue, gross margin, and an increase in general & administrative expenses. The net loss was $(10.6) million, and cash and cash equivalents totaled $7.3 million as of September 30, 2023. The company reaffirmed its revenue guidance for full year 2023 and 2024, expecting 2024 revenue growth of approximately 60% from anticipated 2023 levels.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Spectral AI, Inc. will report financial results for Q3 2023 on November 13, 2023. A conference call to discuss the results will be held on November 14, 2023. Investors can access the webcast of the call on the Company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Spectral AI appoints Prof. Paul Chadwick as Executive VP of its UK subsidiary to expand the international market for its DeepView® wound imaging technology. Prof. Chadwick brings extensive experience in the medical devices and technology sectors, particularly in diabetic wound management.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary
Spectral AI provides annual revenue guidance for 2023 and 2024 and highlights opportunities with its AI-Driven DeepView® Wound Imaging Technology. The company recently secured a contract valued at over $149.0 million from the U.S. Government.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
-
Rhea-AI Summary
Spectral AI's DeepView SnapShot® Wound Imaging System receives UKCA marking and Class 1 medical device classification from FDA
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
AI
Rhea-AI Summary
Spectral AI CEO to participate in Accelerate Health Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences AI
Spectral AI Inc

Nasdaq:MDAIW

MDAIW Rankings

MDAIW Stock Data

22.60M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
DALLAS